Echo Therapeutics Announces Positive Results from Symphony(TM) Transdermal Continuous Glucose Monitoring System Study at Tufts Medi...( FRANKLIN Mass. March 13 /- Echo T...),Health

FRANKLIN, Mass., March 13 /PRNewswire-FirstCall/ -- Echo Therapeutics (OTC Bulletin Board: ECTE) today announced positive results from its clinical study of the Symphony(TM) tCGM System, a novel, non-invasive, transdermal continuous glucose monitoring (tCGM) system, conducted at the Tufts Medical Center in Boston, Massachusetts (Tufts). Echo is developing the Symphony tCGM System to provide patients with diabetes and healthcare professionals with a reliable, needle-free, wireless, continuous monitoring system to better manage diabetes and control blood glucose levels in the home use and hospital critical care settings. Data from the pilot study demonstrate that Symphony safely and reliably monitored blood glucose levels in the challenging operating room and surgical intensive care unit at Tufts. Echo is planning to present these data at a major medical conference later this year.

"We are proud to be the first company to report positive clinical data on a non-invasive, transdermal continuous glucose monitoring system in the hospital critical care setting," stated Patrick Mooney, M.D., Echo's Chairman and CEO. "We are excited about the potential for our program in this area and look forward to continued progress with tCGM in both the home and hospital settings, with further studies planned throughout 2008."

"Critically ill patients need tighter glycemic control to minimize morbidity and mortality," said Stanley Nasraway, M.D., Director of Surgical Intensive Care Units at Tufts and the Principal Investigator of the study. "These data serve as a strong signal that Symphony could advance the standard of care regarding tight glycemic control in the hospital critical care setting, much like continuous electrocardiographic monitoring and pulse oximetry changed standards of care in that setting. This approach could provide doctors and nurses with breakthrough continuous blood glucometry technology and significantly improve our ability to monitor glucose
'/>"/>